Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin

Hypertension Research

Volumn 30, Issue 5, 2007, Pages 387-394

  Derosa, Giuseppe ^a   Fogari, Elena ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Ciccarelli, Leonardina ^a   Piccinni, Mario N ^a   Pricolo, Fabio ^a   Salvadeo, Sibilla A T ^a   Gravina, Alessia ^a   Ferrari, Ilaria ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diabetes mellitus; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; BIGUANIDE; C REACTIVE PROTEIN; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; NITRATE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; ARTICLE; BEHAVIOR MODIFICATION; BICYCLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; FEMALE; GENERAL CONDITION IMPROVEMENT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KINESIOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WALKING;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34250723983     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.387     Document Type: Article

References (29)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis. Epidemiology, Pathophysiology, and Management. JAMA 2002; 287 2570-2581.
2. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman R: Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868-877.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl 1): SI-SI47.
4. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S: Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-834.
5. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (Suppl 6a): 15S-22S.
6. Vague P: Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 2003; 29: 6S5-6S7.
7. Johnson JA, Simpson SH, Majumdar SR, Toth EL: Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
8. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 253: 854-865.
9. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
10. Ovalle F, OvalAe-Berúmen JF: Thiazolidinediones: a review of their benefits and risks. South Med J 2002; 95: 1188-1194.
11. Charbonnel B, Schernthaner G, Brunetti P, et al: Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104.
12. Mooradian AD, Chehade J, Thurman JE: The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1: 13-20.
13. American Diabetes Association: Screening for diabetes (Position Statement). Diabetes Care 2001; 24 (Suppl): S21-S24.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999; 17: 151-183.
16. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva, WHO, 1997.
17. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 (Suppl): S44-S47.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45 2136-2141.
20. 15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
21. Yamauchi T, Kamon J. Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
22. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971.
23. Mancia G: The association of hypertensioP and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42 (Suppl 1): S17-S25.
24. Boyle PJ, King AB, Olansky L, et al: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396.
25. Derosa G, Cicero AF, Gaddi A, et al: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
26. Derosa G, Cicero AFG, D'Angelo A, et al: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28:917-924.
27. Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R: Treatment with rosightazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617-622.
28. Fullert S. Schneider F, Haak E, et al: Effects of pioglitazone in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506.
29. Granberry MC, Fonseca VA: Cardiovascular risk factors associated with insulin resistance: Effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005; 5: 201-209.